| Case–control study of human papillomavirus and oropharyngeal cancer G D'Souza, AR Kreimer, R Viscidi, M Pawlita, C Fakhry, WM Koch, ... New England Journal of Medicine 356 (19), 1944-1956, 2007 | 3530 | 2007 |
| Case-control study of human papillomavirus and oropharyngeal cancer R Viscidi, M Pawlita, WM Koch, WH Westra, ML Gillison The New England Journal of Medicine 356 (19), 1944, 2007 | 3530 | 2007 |
| Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers ML Gillison, G D'Souza, W Westra, E Sugar, W Xiao, S Begum, R Viscidi Journal of the National Cancer Institute 100 (6), 407-420, 2008 | 1983 | 2008 |
| Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study R Herrero, X Castellsagué, M Pawlita, J Lissowska, F Kee, P Balaram, ... Journal of the National Cancer Institute 95 (23), 1772-1783, 2003 | 1783 | 2003 |
| Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations R Viscidi, S Willey, JG Bartlett Gastroenterology 81 (1), 5-9, 1981 | 517 | 1981 |
| Association between the vaginal microbiota, menopause status and signs of vulvovaginal atrophy RM Brotman, MD Shardell, P Gajer, D Fadrosh, K Chang, M Silver, ... Menopause (New York, NY) 21 (5), 450, 2014 | 512* | 2014 |
| Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens TC Wu, FG Guarnieri, KF Staveley-O'Carroll, RP Viscidi, HI Levitsky, ... Proceedings of the National Academy of Sciences 92 (25), 11671-11675, 1995 | 447 | 1995 |
| Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1 RP Viscidi, K Mayur, HM Lederman, AD Frankel Science 246 (4937), 1606-1608, 1989 | 430 | 1989 |
| Clinician's guide to human papillomavirus immunology: knowns and unknowns MH Einstein, JT Schiller, RP Viscidi, HD Strickler, P Coursaget, T Tan, ... The Lancet infectious diseases 9 (6), 347-356, 2009 | 354 | 2009 |
| Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships TC Quinn, C Gaydos, M Shepherd, L Bobo, EW Hook, R Viscidi, ... Jama 276 (21), 1737-1742, 1996 | 318 | 1996 |
| Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica RP Viscidi, M Schiffman, A Hildesheim, R Herrero, PE Castle, MC Bratti, ... Cancer Epidemiology and Prevention Biomarkers 13 (2), 324-327, 2004 | 261 | 2004 |
| Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms EG Severance, FB Dickerson, RP Viscidi, I Bossis, CR Stallings, ... Schizophrenia bulletin 37 (1), 101-107, 2011 | 244 | 2011 |
| Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus TW Kim, JH Lee, CF Hung, S Peng, R Roden, MC Wang, R Viscidi, ... Journal of virology 78 (9), 4638-4645, 2004 | 244 | 2004 |
| Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada J Pintos, MJ Black, N Sadeghi, P Ghadirian, AG Zeitouni, RP Viscidi, ... Oral oncology 44 (3), 242-250, 2008 | 243 | 2008 |
| A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3 CL Trimble, S Peng, F Kos, P Gravitt, R Viscidi, E Sugar, D Pardoll, TC Wu Clinical Cancer Research 15 (1), 361-367, 2009 | 232 | 2009 |
| Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus RP Viscidi, DE Rollison, VK Sondak, B Silver, JL Messina, AR Giuliano, ... Clin. Vaccine Immunol. 18 (10), 1737-1743, 2011 | 228 | 2011 |
| Asymptomatic reactivation of JC virus in patients treated with natalizumab Y Chen, E Bord, T Tompkins, J Miller, CS Tan, RP Kinkel, MC Stein, ... New England Journal of Medicine 361 (11), 1067-1074, 2009 | 226 | 2009 |
| Population genetics of microbial pathogens estimated from multilocus sequence typing (MLST) data M Pérez-Losada, EB Browne, A Madsen, T Wirth, RP Viscidi, KA Crandall Infection, Genetics and Evolution 6 (2), 97-112, 2006 | 200 | 2006 |
| Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer M Moller, RP Viscidi, Y Sun, E Guerrero, PM Hill, F Shah, FX Bosch, ... Virology 187 (2), 508-514, 1992 | 200 | 1992 |
| Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10 000 women in Costa Rica SS Wang, M Schiffman, TS Shields, R Herrero, A Hildesheim, MC Bratti, ... British journal of cancer 89 (7), 1248-1254, 2003 | 180 | 2003 |
